Metformin and Malignant Tumors: Not Over the Hill

Weiling Leng,1,* Juan Jiang,2,* Bing Chen,1 Qinan Wu3 1Endocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China; 2Endocrinology and Nephrology Department, Chongqing University Cancer Ho...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Leng W, Jiang J, Chen B, Wu Q
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	metformin malignant tumor type 2 diabetes mellitus insulin resistance 5’ adenosine monophosphate-activated protein kinase;antitumor Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/006ef183f96249318c689f215edb1891
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:006ef183f96249318c689f215edb1891
record_format	dspace
spelling	oai:doaj.org-article:006ef183f96249318c689f215edb18912021-12-02T16:45:44ZMetformin and Malignant Tumors: Not Over the Hill1178-7007https://doaj.org/article/006ef183f96249318c689f215edb18912021-08-01T00:00:00Zhttps://www.dovepress.com/metformin-and-malignant-tumors-not-over-the-hill-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Weiling Leng,1,* Juan Jiang,2,* Bing Chen,1 Qinan Wu3 1Endocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China; 2Endocrinology and Nephrology Department, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, People’s Republic of China; 3Endocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qinan WuEndocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing, People’s Republic of ChinaEmail wqn11@126.comBing ChenEndocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, People’s Republic of ChinaEmail chenbingxnyy@126.comAbstract: Malignant tumors are a major cause of death, and their incidence is increasing worldwide. Although the survival rate for some cancers has improved, treatments for other malignant tumors are limited, and their mortality rate continues to increase. People with type 2 diabetes have a higher risk of malignant tumors and a higher mortality rate than those without diabetes. Metformin is a commonly used hypoglycemic drug. In recent years, a growing number of studies have indicated that metformin has antitumor effects and increases the sensitivity of malignant tumors to chemotherapy. However, the effect of metformin on different tumors is currently controversial, and the mechanism of metformin’s antitumor action is not fully understood. Insights into the effect of metformin on malignant tumors and the possible mechanism may contribute to the development of antitumor drugs.Keywords: metformin, malignant tumor, type 2 diabetes mellitus, insulin resistance, 5’ adenosine monophosphate-activated protein kinase, antitumorLeng WJiang JChen BWu QDove Medical Pressarticlemetforminmalignant tumortype 2 diabetes mellitusinsulin resistance5’ adenosine monophosphate-activated protein kinase;antitumorSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 3673-3689 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metformin malignant tumor type 2 diabetes mellitus insulin resistance 5’ adenosine monophosphate-activated protein kinase;antitumor Specialties of internal medicine RC581-951
spellingShingle	metformin malignant tumor type 2 diabetes mellitus insulin resistance 5’ adenosine monophosphate-activated protein kinase;antitumor Specialties of internal medicine RC581-951 Leng W Jiang J Chen B Wu Q Metformin and Malignant Tumors: Not Over the Hill
description	Weiling Leng,1,* Juan Jiang,2,* Bing Chen,1 Qinan Wu3 1Endocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, People’s Republic of China; 2Endocrinology and Nephrology Department, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, People’s Republic of China; 3Endocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Qinan WuEndocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing, People’s Republic of ChinaEmail wqn11@126.comBing ChenEndocrinology Department, The First Affiliated Hospital of the Third Military Medical University (Army Medical University), Chongqing, People’s Republic of ChinaEmail chenbingxnyy@126.comAbstract: Malignant tumors are a major cause of death, and their incidence is increasing worldwide. Although the survival rate for some cancers has improved, treatments for other malignant tumors are limited, and their mortality rate continues to increase. People with type 2 diabetes have a higher risk of malignant tumors and a higher mortality rate than those without diabetes. Metformin is a commonly used hypoglycemic drug. In recent years, a growing number of studies have indicated that metformin has antitumor effects and increases the sensitivity of malignant tumors to chemotherapy. However, the effect of metformin on different tumors is currently controversial, and the mechanism of metformin’s antitumor action is not fully understood. Insights into the effect of metformin on malignant tumors and the possible mechanism may contribute to the development of antitumor drugs.Keywords: metformin, malignant tumor, type 2 diabetes mellitus, insulin resistance, 5’ adenosine monophosphate-activated protein kinase, antitumor
format	article
author	Leng W Jiang J Chen B Wu Q
author_facet	Leng W Jiang J Chen B Wu Q
author_sort	Leng W
title	Metformin and Malignant Tumors: Not Over the Hill
title_short	Metformin and Malignant Tumors: Not Over the Hill
title_full	Metformin and Malignant Tumors: Not Over the Hill
title_fullStr	Metformin and Malignant Tumors: Not Over the Hill
title_full_unstemmed	Metformin and Malignant Tumors: Not Over the Hill
title_sort	metformin and malignant tumors: not over the hill
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/006ef183f96249318c689f215edb1891
work_keys_str_mv	AT lengw metforminandmalignanttumorsnotoverthehill AT jiangj metforminandmalignanttumorsnotoverthehill AT chenb metforminandmalignanttumorsnotoverthehill AT wuq metforminandmalignanttumorsnotoverthehill
_version_	1718383433301884928

Metformin and Malignant Tumors: Not Over the Hill

Ejemplares similares